Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 15/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 14/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536775 | 1.00 | CNR2 (0.43) | CNR2CNR1ADORA2AADORA2BADORA1 | |
| SCHEMBL536819 | 0.98 | CNR2 (0.43) | CNR2CNR1ADORA2AADORA2BADORA1 | |
| SCHEMBL537077 | 0.91 | ADORA2A (0.41) | CNR2CNR1ADORA2AADORA2BADORA1 | |
| SCHEMBL536343 | 0.86 | ADORA2A (0.45) | CNR2CNR1ADORA2AADORA2BADORA1 | |
| SCHEMBL536587 | 0.84 | ADORA2A (0.45) | CNR2CNR1ADORA2AADORA2BADORA1 | |
| SCHEMBL536712 | 0.82 | ADORA2A (0.39) | CNR2ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL536748 | 0.81 | ADORA2A (0.59) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL21814389 | 0.81 | ADORA2A (0.43) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL536715 | 0.80 | ADORA2A (0.57) | CNR2CNR1ADORA2AADORA2BADORA1 | |
| SCHEMBL536820 | 0.80 | ADORA2A (0.49) | ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | CNR2 324/4885CNR1 231/4885ADORA2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.